Medicenna Announces Changes to Board Composition

Core Viewpoint - Medicenna Therapeutics Corp. has appointed Mr. Richard Sutin and Mr. Angelos Georgakis to its board of directors, effective February 12, 2026, following the retirement of Ms. Karen Dawes [1][2][3]. Group 1: Board Appointments - Mr. Richard Sutin brings extensive knowledge in capital markets and mergers and acquisitions, while Mr. Angelos Georgakis has experience advising biotech leadership through critical inflection points [2]. - The appointments are expected to enhance the company's growth and stewardship, creating long-term value for stakeholders [2]. - Ms. Karen Dawes, who served on the board since 2019, has retired, and the board expressed gratitude for her contributions [3][4]. Group 2: Background of New Directors - Angelos Georgakis is a strategic advisor to biotech leaders and has a history of helping executives navigate financing and acquisitions [5]. - Richard Sutin has a background in corporate legal services and has been recognized as a leading lawyer in corporate mid-market transactions [6]. Group 3: Company Overview - Medicenna is a clinical-stage immunotherapy company focused on developing novel Superkines, including long-acting IL-2 Superkine MDNA11 and targeted PD-1 x IL-2 bispecific MDNA113 [7]. - The company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in multiple clinical trials and has received FastTrack and Orphan Drug status from the FDA [7].